Proactive Investors - Run By Investors For Investors

Stitch Fix Inc stock drops after quarterly sales miss expectations

Katrina Lake, Stich Fix founder and chief executive, described the numbers as “strong results", nonetheless the headline number was less than expected
online shopping
The stock dropped ahead of the open

Stitch Fix Inc (NASDAQ:SFIX) stock dropped more than 5% ahead of Tuesday’s open in New York after the personal shopping app maker posted results below expectations.

Net income for the second quarter amounted to US$3.6mln, equating to 2 US cents per share, on US$295.9mln of revenue.

Active clients rose by 31% year-on-year

Wall Street consensus was pitched at 6 US cents per share on US$291mln of revenue, so naturally the market was disappointed.

Looking to the current period, Stitch Fix said it is expecting to generate US$300mln to US$310mln of sales, and the full year revenue figure is pitched at US$1.19bn to US$1.22bn.

Katrina Lake, Stitch Fix founder and chief executive, described the numbers as “strong results”.

“We grew our active clients to 2.5 million, an increase of 588,000 and 31% year-over-year. We grew net revenue to $295.9 million, representing 24% year-over-year growth,” Lake said.

“This quarter also marked the fourth consecutive quarter that we grew net revenue in the range of 25% year-over-year.

“In addition to strong momentum across our men’s and women’s categories, we’re excited about the potential of Extras, a new capability that allows us to serve more of our client’s wardrobe, while increasing incremental revenue.”

Stitch Fix shares were down US$1.32 or 5.47% changing hands at US$22.80 before Tuesday’s open.

View full INDU profile View Profile

US Market News Timeline

Newswire
March 15 2018

Related Articles

woman at a microscope
August 02 2018
Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system
Oncoprex
October 17 2018
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use